LitCovid-sentences  

PMC:7102662 / 46-1648 JSONTXT 10 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T3 0-19 Sentence denotes Background and aims
T4 20-184 Sentence denotes Many patients with coronavirus disease 2019 (COVID-19) have underlying cardiovascular (CV) disease or develop acute cardiac injury during the course of the illness.
T5 185-310 Sentence denotes Adequate understanding of the interplay between COVID-19 and CV disease is required for optimum management of these patients.
T6 312-319 Sentence denotes Methods
T7 320-432 Sentence denotes A literature search was done using PubMed and Google search engines to prepare a narrative review on this topic.
T8 434-441 Sentence denotes Results
T9 442-555 Sentence denotes Respiratory illness is the dominant clinical manifestation of COVID-19; CV involvement occurs much less commonly.
T10 556-695 Sentence denotes Acute cardiac injury, defined as significant elevation of cardiac troponins, is the most commonly reported cardiac abnormality in COVID-19.
T11 696-745 Sentence denotes It occurs in approximately 8–12% of all patients.
T12 746-925 Sentence denotes Direct myocardial injury due to viral involvement of cardiomyocytes and the effect of systemic inflammation appear to be the most common mechanisms responsible for cardiac injury.
T13 926-1011 Sentence denotes The information about other CV manifestations in COVID-19 is very limited at present.
T14 1012-1210 Sentence denotes Nonetheless, it has been consistently shown that the presence of pre-existing CV disease and/or development of acute cardiac injury are associated with significantly worse outcome in these patients.
T15 1212-1223 Sentence denotes Conclusions
T16 1224-1328 Sentence denotes Most of the current reports on COVID-19 have only briefly described CV manifestations in these patients.
T17 1329-1602 Sentence denotes Given the enormous burden posed by this illness and the significant adverse prognostic impact of cardiac involvement, further research is required to understand the incidence, mechanisms, clinical presentation and outcomes of various CV manifestations in COVID-19 patients.